|This Slide: #64 of 100|
Slide #64. AMRI — Cedarburg Pharmaceuticals, Inc.
Cedarburg Pharmaceuticals, Inc.
AMRI (NASDAQ: AMRI) today announced that it has signed a definitive agreement to acquire all the outstanding shares of Cedarburg Pharmaceuticals, Inc. for $38.2 million in cash. The transaction, including $2.8 million of assumed liabilities, is valued at $41 million. Cedarburg Pharmaceuticals is a contract developer and manufacturer of technically complex active pharmaceutical ingredients (API's) for both generic and branded customers. The transaction is consistent with AMRI's strategy to be the preeminent supplier of custom and complex drug development services and product to both the branded and generic pharmaceutical industry.
Albany Molecular Research is a contract research and manufacturing organization providing customers integrated drug discovery, development, and manufacturing services. Co. has three segments: Discovery and Development Services, which include provides a range of chemical development technologies for route development; Active Pharmaceutical Ingredients, which provides chemical synthesis and manufacturing services for its customers; drug product, which provides facilities to deliver integrated pharmaceutical drug development programs and services; and Fine Chemicals, which provides lab to commercial scale synthesis of reagents and diverse compounds to the pharmaceutical, among others.
Open the AMRI Page at The Online Investor »
Free AMRI Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Hold (2.00 out of 4)
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite